Prostate Cancer Clinical Trials in Pittsburgh

Showing 201-220 of 381 trials

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04227275

Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells (CART-PSMA-TGFβRDN cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T cell.

Metastatic Castration-resistant Prostate Cancer

Tceleron Therapeutics, Inc.16 participantsStarted Nov 2019

Tampa, Florida, United States • Kansas City, Kansas, United States • St Louis, Missouri, United States +6 more locations

TERMINATEDPhase 2< 1 mile

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

NCT01326312

The purpose of this study is to determine whether GTx 758 is effective in achieving and maintaining castrate testosterone levels in men with advanced prostate cancer.

Prostate Cancer

GTx159 participantsStarted Jun 2011

Phoenix, Arizona, United States • La Mesa, California, United States • Los Angeles, California, United States +33 more locations

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

Prostate Cancer Trials in Other Cities

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

A Study of FT-7051 in Men With MCRPC

Pioneering Advances in Care and Education (PACE)

Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer

Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Other Conditions in Pittsburgh